FDA Confirms Endpoints of Androxal Study By: Benzinga via Benzinga July 16, 2014 at 09:21 AM EDT Repros Therapeutics Inc.® (Nasdaq: RPRX) today announced it has received additional guidance from the FDA regarding primary endpoints ... Read More >>